FDA – Safety Report

FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering

FDA Drug Safety Communication

A safety announcement by the FDA on the dangers of rapid discontinuation of opioid medication with patients who are physically dependent.

Read the article here.